News

Manufacturing and scale-up of industrialized processes to manufacture gene therapy products are accompanied by many challenges that must be overcome to succeed in the marketplace. Commercialization of gene therapies for patient use is time consuming and requires substantial financial...

Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced that Paraguay's Ministry of Public Health and Social Welfare (MSPBS) has granted an emergency use authorization (EUA) for proxalutamide to treat hospitalized patients with...

The UK Government has announced plans to commence a research programme comprising of 15 new studies to develop new therapies for long Covid and enhance diagnosis. As per the National Institute for Health and Care Excellence (NICE) guidance, long Covid...

Kintor Pharmaceutical Limited announced that it has entered into a licensing agreement with Shanghai Fosun Pharmaceutical Development Ltd., on the commercialisation of proxalutamide for the treatment of Covid-19 indication in India and 28 African countries. Kintor and Fosun Pharma Development...

Fusion Antibodies, pre-clinical antibody discovery and development experts and BioTickle, their exclusive distributor in India, are providing local biopharmaceutical organisations with access to invaluable unique biopharmaceutical development capabilities. As Dr Richard Jones, CEO of Fusion Antibodies explains, "We are proud...

Cognizant announced it has agreed to acquire TQS Integration, a privately owned global industrial data and intelligence company based in Lismore, Ireland. TQS delivers manufacturing data intelligence, global technology consulting and digital systems integration to help manufacturers accelerate their...

In conjunction with the IAS Conference on HIV Science, Frontier Biotechnologies announced positive top-line results for its phase 3 TALENT study, which demonstrated that an ABT-based two-drug treatment arm was non-inferior to a lopinavir (LPV)-based three-drug arm (75.7% vs...